Vittorio Fasulo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vittorio Fasulo has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Lughezzani
Department of Urology, IRCCS Humanitas Clinical and Research Hospital, 20089 Rozzano, Italy
15 shared publications - Massimo Lazzeri
Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy
15 shared publications - Rodolfo Hurle
Department of Urology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
15 shared publications - Paolo Casale
Department of Urology IRCCS Humanitas Research Hospital Rozzano Italy
13 shared publications - Marco Paciotti
Department of Biomedical Sciences Humanitas University Milan Italy
12 shared publications - Pier Paolo Avolio
Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy
12 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in European Urology
- Vol. 90 (5) , 520-521
Re: Prostate Cancer
- 17 August 2026
- Published by Wiley in BJU International
- Vol. 138 (5) , 786-797
Artificial intelligence for predicting BCG response in non‐muscle‐invasive bladder cancer: a systematic review
Objectives: To systematically identify, appraise and synthesise artificial intelligence (AI) and machine‐learning (ML) models that predict treatment response and clinical outcomes after intravesical bacillus Calmette–Guérin (BCG) in non‐muscle‐invasive bladder cancer (NMIBC), a setting in which current risk calculators underperform, and identifying non‐responders has become urgent as alternatives to BCG enter practice. Methods: PubMed, EMBASE and Web of Science were searched through April 2026 following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020 guidelines (International Prospective Register of Systematic Reviews [PROSPERO] number CRD420261376808). Studies developing or validating AI/ML models for BCG‐associated outcomes with a quantitative performance metric were included. Risk of bias was assessed with the Prediction model Risk Of Bias ASsessment Tool (PROBAST). Evidence was synthesised along a clinically oriented framework: AI as a perceptual tool (extracting signal from histology or imaging) or integrative tool (re‐weighting clinicopathological, molecular, or urinary variables). Results: A total of 15 studies (>24 900 patients) were included: seven perceptual, eight integrative. By input data, six used digital pathology, two radiomics, two genomics/transcriptomics, four clinicopathological markers, and one urinary biomarkers. The digital‐pathology Computational Histology Artificial Intelligence (CHAI) platform, validated across 12 international centres, stratified high‐grade recurrence (hazard ratio [HR] 2.08), progression (HR 3.87) and BCG‐unresponsive disease (HR 2.31), and was the only model providing a first signal of predictive value, demonstrating a significant BCG vs gemcitabine/docetaxel interaction ( P = 0.029). Integrative models PROGRxN‐BCa (concordance index [C‐index] 0.79) and DeepSurv (C‐index 0.881) outperformed standard calculators but with modest gains (ΔC‐index 0.05–0.10). Only 40% of studies performed external validation, none prospectively; five were at high risk of bias. Conclusion: Perceptual AI, particularly digital pathology, has the highest external validation and provides the only biomarker with a first signal of predictive value for BCG vs alternatives, increasingly relevant in the context of the global BCG shortage. Integrative models such as PROGRxN‐BCa and DeepSurv outperform standard calculators with incremental gains and are freely accessible. Prospective validation, systematic calibration reporting and treatment‐by‐biomarker interaction analyses, ideally embedded in trials such as the BRIDGE trial (ClinicalTrials.gov identifier: NCT05538663), remain priorities before clinical adoption.
- 17 August 2026
- Published by Wiley in BJU International
- Vol. 138 (5) , 786-797
Artificial intelligence for predicting BCG response in non‐muscle‐invasive bladder cancer: a systematic review
Objectives: To systematically identify, appraise and synthesise artificial intelligence (AI) and machine‐learning (ML) models that predict treatment response and clinical outcomes after intravesical bacillus Calmette–Guérin (BCG) in non‐muscle‐invasive bladder cancer (NMIBC), a setting in which current risk calculators underperform, and identifying non‐responders has become urgent as alternatives to BCG enter practice. Methods: PubMed, EMBASE and Web of Science were searched through April 2026 following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020 guidelines (International Prospective Register of Systematic Reviews [PROSPERO] number CRD420261376808). Studies developing or validating AI/ML models for BCG‐associated outcomes with a quantitative performance metric were included. Risk of bias was assessed with the Prediction model Risk Of Bias ASsessment Tool (PROBAST). Evidence was synthesised along a clinically oriented framework: AI as a perceptual tool (extracting signal from histology or imaging) or integrative tool (re‐weighting clinicopathological, molecular, or urinary variables). Results: A total of 15 studies (>24 900 patients) were included: seven perceptual, eight integrative. By input data, six used digital pathology, two radiomics, two genomics/transcriptomics, four clinicopathological markers, and one urinary biomarkers. The digital‐pathology Computational Histology Artificial Intelligence (CHAI) platform, validated across 12 international centres, stratified high‐grade recurrence (hazard ratio [HR] 2.08), progression (HR 3.87) and BCG‐unresponsive disease (HR 2.31), and was the only model providing a first signal of predictive value, demonstrating a significant BCG vs gemcitabine/docetaxel interaction ( P = 0.029). Integrative models PROGRxN‐BCa (concordance index [C‐index] 0.79) and DeepSurv (C‐index 0.881) outperformed standard calculators but with modest gains (ΔC‐index 0.05–0.10). Only 40% of studies performed external validation, none prospectively; five were at high risk of bias. Conclusion: Perceptual AI, particularly digital pathology, has the highest external validation and provides the only biomarker with a first signal of predictive value for BCG vs alternatives, increasingly relevant in the context of the global BCG shortage. Integrative models such as PROGRxN‐BCa and DeepSurv outperform standard calculators with incremental gains and are freely accessible. Prospective validation, systematic calibration reporting and treatment‐by‐biomarker interaction analyses, ideally embedded in trials such as the BRIDGE trial (ClinicalTrials.gov identifier: NCT05538663), remain priorities before clinical adoption.
- Open Access
Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial
Background and Objective: Transurethral resection of bladder tumor (TURBT) is the standard for non-muscle-invasive bladder cancer (NMIBC), yet recurrence rates remain high. This study evaluates the safety, tolerability, and efficacy of neoadjuvant intravesical mitomycin C (neoMMC) before TURBT in reducing recurrence and improving surgical outcomes. Methods: This randomized phase III trial enrolled patients with primary or recurrent NMIBC. Participants were randomized 1:1 to a neoadjuvant group receiving two instillations of MMC (day −14 and −7) before TURBT, or a control group undergoing standard TURBT without neoadjuvant treatment. The primary endpoint was 12-month recurrence-free survival (RFS). Secondary endpoints included surgical quality (complete resection, cauterization only, absence of residual tumor) and safety. Exploratory endpoints included histopathologic response and time to recurrence. Key Findings and Limitations: Among 95 patients (48 neoMMC, 47 controls), baseline characteristics were balanced. After a median follow-up of 19.4 months, recurrences occurred in 9 StA and 4 NeoA patients, with one progression to MIBC in the NeoA arm. RFS did not differ significantly between groups at 12 or 18 months. Neoadjuvant MMC was well tolerated, with only grade 1–2 AEs. Exploratory microbiota analyses suggested that neoadjuvant MMC modulated urinary microbial diversity and was associated with a microbiota profile more similar to that observed in non-recurrent patients. Limitations include single-center design and relatively short follow-up. Conclusions and Clinical Implications: Neoadjuvant intravesical MMC before TURBT was feasible and well tolerated in patients with NMIBC, with no unexpected safety signals. In this prematurely terminated and underpowered trial, no significant improvement in RFS was observed. Larger adequately powered studies are needed to clarify the oncologic efficacy of this approach.
Open AccessNeoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial
Background and Objective: Transurethral resection of bladder tumor (TURBT) is the standard for non-muscle-invasive bladder cancer (NMIBC), yet recurrence rates remain high. This study evaluates the safety, tolerability, and efficacy of neoadjuvant intravesical mitomycin C (neoMMC) before TURBT in reducing recurrence and improving surgical outcomes. Methods: This randomized phase III trial enrolled patients with primary or recurrent NMIBC. Participants were randomized 1:1 to a neoadjuvant group receiving two instillations of MMC (day −14 and −7) before TURBT, or a control group undergoing standard TURBT without neoadjuvant treatment. The primary endpoint was 12-month recurrence-free survival (RFS). Secondary endpoints included surgical quality (complete resection, cauterization only, absence of residual tumor) and safety. Exploratory endpoints included histopathologic response and time to recurrence. Key Findings and Limitations: Among 95 patients (48 neoMMC, 47 controls), baseline characteristics were balanced. After a median follow-up of 19.4 months, recurrences occurred in 9 StA and 4 NeoA patients, with one progression to MIBC in the NeoA arm. RFS did not differ significantly between groups at 12 or 18 months. Neoadjuvant MMC was well tolerated, with only grade 1–2 AEs. Exploratory microbiota analyses suggested that neoadjuvant MMC modulated urinary microbial diversity and was associated with a microbiota profile more similar to that observed in non-recurrent patients. Limitations include single-center design and relatively short follow-up. Conclusions and Clinical Implications: Neoadjuvant intravesical MMC before TURBT was feasible and well tolerated in patients with NMIBC, with no unexpected safety signals. In this prematurely terminated and underpowered trial, no significant improvement in RFS was observed. Larger adequately powered studies are needed to clarify the oncologic efficacy of this approach.
- Open Access
AI in High-Frequency Micro-Ultrasound: Advancing Prostate Imaging from Segmentation to Cancer Detection
Background/Objective: High-frequency micro-ultrasound (micro-US) offers real-time, high-resolution imaging for prostate cancer. Although artificial intelligence (AI) has shown potential in enhancing micro-US interpretation, a comprehensive review of this emerging field is currently missing. This review synthesizes current evidence on AI applied to ExactVu 29 MHz micro-US for prostate cancer. Methods: PubMed/MEDLINE, Embase, Scopus, Web of Science and the Cochrane Library were searched up to December 2025. Studies were included if they applied machine learning or deep learning directly to 29 MHz micro-US data and reported quantitative performance metrics. Results: Ten studies met the inclusion criteria: six on prostate cancer detection, three on prostate segmentation and one on micro-US–histopathology registration. Detection models ranged from classical quantitative ultrasound machine learning to deep architectures using self-supervision, transformers, multiple-instance learning, ensemble calibration and 3D segmentation-based pipelines. Among core-level models for clinically significant cancer, area under the receiver operating characteristic curve (AUROC) values clustered around 0.76–0.81; one lesion-level framework reported an AUROC of 0.92, though at a non-comparable analytical unit. Segmentation studies achieved accurate prostate delineation (Dice similarity coefficient ≈ 0.94), and a single study demonstrated high-precision 3D registration to whole-mount histopathology (Dice similarity coefficient 0.97 and landmark error < 3 mm). All studies evaluated AI on previously acquired data, without real-time clinical implementation. Conclusions: AI for micro-US shows promising and reproducible early results across detection, segmentation and registration, but evidence is still limited. In view of the potential of AI to optimize micro-US utilization and its related advantages, additional efforts are warranted to achieve clinical adoption.
Open AccessAI in High-Frequency Micro-Ultrasound: Advancing Prostate Imaging from Segmentation to Cancer Detection
Background/Objective: High-frequency micro-ultrasound (micro-US) offers real-time, high-resolution imaging for prostate cancer. Although artificial intelligence (AI) has shown potential in enhancing micro-US interpretation, a comprehensive review of this emerging field is currently missing. This review synthesizes current evidence on AI applied to ExactVu 29 MHz micro-US for prostate cancer. Methods: PubMed/MEDLINE, Embase, Scopus, Web of Science and the Cochrane Library were searched up to December 2025. Studies were included if they applied machine learning or deep learning directly to 29 MHz micro-US data and reported quantitative performance metrics. Results: Ten studies met the inclusion criteria: six on prostate cancer detection, three on prostate segmentation and one on micro-US–histopathology registration. Detection models ranged from classical quantitative ultrasound machine learning to deep architectures using self-supervision, transformers, multiple-instance learning, ensemble calibration and 3D segmentation-based pipelines. Among core-level models for clinically significant cancer, area under the receiver operating characteristic curve (AUROC) values clustered around 0.76–0.81; one lesion-level framework reported an AUROC of 0.92, though at a non-comparable analytical unit. Segmentation studies achieved accurate prostate delineation (Dice similarity coefficient ≈ 0.94), and a single study demonstrated high-precision 3D registration to whole-mount histopathology (Dice similarity coefficient 0.97 and landmark error < 3 mm). All studies evaluated AI on previously acquired data, without real-time clinical implementation. Conclusions: AI for micro-US shows promising and reproducible early results across detection, segmentation and registration, but evidence is still limited. In view of the potential of AI to optimize micro-US utilization and its related advantages, additional efforts are warranted to achieve clinical adoption.
- Open Access
- 12 June 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (12) , 1492
An Evaluation of the Diagnostic Accuracy of [68Ga]Ga-PSMA-11 vs. [18F]F-PSMA-1007 PET/CT for Lymph Node Staging in Patient Candidates for Radical Prostatectomy and Lymph Node Dissection: A Single Institutional Analysis
Background/Objectives: This study evaluates and compares the diagnostic accuracy of [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 for lymph node staging in patients with prostate cancer (PCa) scheduled for robot-assisted radical prostatectomy (RARP) and lymphadenectomy (LND). Methods: We retrospectively reviewed prospectively collected data on patients referred to our hospital from October 2020 to January 2023. We included all patients who underwent [68Ga]Ga-PSMA-11 or [18F]F-PSMA-1007 PET/CT for primary staging and subsequently had RARP with concomitant LND. The maximum standard uptake value (SUVmax) for lymph nodes (LNs) and the SUV node-to-background ratio were reported. Two different cut-off values for the SUV node-to-background ratio (i.e., ≥2 vs. <2 and ≥15.5 vs. <15.5) were used to evaluate the diagnostic performance of both tracers. The first cut-off was empirically chosen, while the second was based on Liu’s method. Results: A total of 156 patients were included (median age: 67 years). Among them, 83 underwent [68Ga]Ga-PSMA-11 and 73 underwent [18F]F-PSMA-1007 PET/CT. Suspicious lymph nodes were identified in 21 patients (13.5%). Pathological nodal involvement (pN1) was confirmed in 25 cases (16%). Of the 21 patients with suspicious pathological lymph nodes on PSMA PET/CT, 9 (42.9%) had positive nodes on the final pathology report. With an SUV node-to-background ratio cut-off of ≥2, [68Ga]Ga-PSMA-11 showed 37.5% sensitivity (SE) and 98.5% specificity(SP), while [18F]F-PSMA-1007 demonstrated 33.3% SE and 100% SP. Using the ≥15.5 cut-off, SE and SP were 31.3% and 100% for [68Ga]Ga-PSMA-11 and 11.1% and 100% for [18F]F-PSMA-1007, respectively. Conclusions: [18F]F-PSMA-1007 PET/CT showed, even if not statistically significantly, slightly lower SE and higher SP for nodal staging compared to [68Ga]Ga-PSMA-11 PET/CT, irrespective of the SUV ratio used.
- 12 June 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (12) , 1492
Open AccessAn Evaluation of the Diagnostic Accuracy of [68Ga]Ga-PSMA-11 vs. [18F]F-PSMA-1007 PET/CT for Lymph Node Staging in Patient Candidates for Radical Prostatectomy and Lymph Node Dissection: A Single Institutional Analysis
Background/Objectives: This study evaluates and compares the diagnostic accuracy of [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 for lymph node staging in patients with prostate cancer (PCa) scheduled for robot-assisted radical prostatectomy (RARP) and lymphadenectomy (LND). Methods: We retrospectively reviewed prospectively collected data on patients referred to our hospital from October 2020 to January 2023. We included all patients who underwent [68Ga]Ga-PSMA-11 or [18F]F-PSMA-1007 PET/CT for primary staging and subsequently had RARP with concomitant LND. The maximum standard uptake value (SUVmax) for lymph nodes (LNs) and the SUV node-to-background ratio were reported. Two different cut-off values for the SUV node-to-background ratio (i.e., ≥2 vs. <2 and ≥15.5 vs. <15.5) were used to evaluate the diagnostic performance of both tracers. The first cut-off was empirically chosen, while the second was based on Liu’s method. Results: A total of 156 patients were included (median age: 67 years). Among them, 83 underwent [68Ga]Ga-PSMA-11 and 73 underwent [18F]F-PSMA-1007 PET/CT. Suspicious lymph nodes were identified in 21 patients (13.5%). Pathological nodal involvement (pN1) was confirmed in 25 cases (16%). Of the 21 patients with suspicious pathological lymph nodes on PSMA PET/CT, 9 (42.9%) had positive nodes on the final pathology report. With an SUV node-to-background ratio cut-off of ≥2, [68Ga]Ga-PSMA-11 showed 37.5% sensitivity (SE) and 98.5% specificity(SP), while [18F]F-PSMA-1007 demonstrated 33.3% SE and 100% SP. Using the ≥15.5 cut-off, SE and SP were 31.3% and 100% for [68Ga]Ga-PSMA-11 and 11.1% and 100% for [18F]F-PSMA-1007, respectively. Conclusions: [18F]F-PSMA-1007 PET/CT showed, even if not statistically significantly, slightly lower SE and higher SP for nodal staging compared to [68Ga]Ga-PSMA-11 PET/CT, irrespective of the SUV ratio used.
- 7 May 2025
- Published by Springer Nature
- p. 665-674
Micro-Ultrasound for the Diagnosis and Characterization of Prostate Cancer
- 7 May 2025
- Published by Springer Nature
- p. 665-674
Micro-Ultrasound for the Diagnosis and Characterization of Prostate Cancer
- 29 January 2025
- Published by SAGE Publications in Clinical Rehabilitation
- Vol. 39 (3) , 295-305
Effects of a home-based pelvic floor muscle training with and without action and cue observation on urinary incontinence after prostatectomy: A randomized controlled trial
Objective: To investigate the effects of a home-based pelvic floor muscle training with and without action and cue observation on urinary incontinence after prostatectomy. Design: Two-armed single-blind randomized controlled trial. Setting: Humanitas Research Hospital, Milan, Italy. Participants: Ninety-two participants with age between 40 and 80 years and urinary incontinence after robot-assisted laparoscopic prostatectomy. Intervention: Participants were randomized into an action and cue observation ( n = 46) or control ( n = 46) group undergoing an 8-week home-based pelvic floor muscle training. Action and cue observation group observed video clips showing exercises synchronized with a visual cue indicating the correct pelvic floor muscle activation timing and imitated the observed tasks. Control group observed landscape video clips and performed the same exercises of experimental group. Main measures: A blinded physiotherapist assessed participants for urinary leakages (24-h pad test), symptom severity (International Prostate Symptoms Score and International Prostate Symptoms Score - Quality of Life), quality of life (International Consultation on Incontinence Questionnaire - Short Form), and erectile dysfunction (International Index of Erectile Function) before and after the training. Results: All participants improved urinary leakages, symptom severity, and quality of life after training. Action and cue observation group revealed significantly larger improvements in 24-h pad test (mean difference: 106.1 g, 95% CI: 13.4 g, 199.1 g, p = .037) than control group. Conclusions: Home-based pelvic floor muscle training with action and cue observation led to larger improvements in urinary continence compared to the same training without action and cue observation after prostatectomy.
- 29 January 2025
- Published by SAGE Publications in Clinical Rehabilitation
- Vol. 39 (3) , 295-305
Effects of a home-based pelvic floor muscle training with and without action and cue observation on urinary incontinence after prostatectomy: A randomized controlled trial
Objective: To investigate the effects of a home-based pelvic floor muscle training with and without action and cue observation on urinary incontinence after prostatectomy. Design: Two-armed single-blind randomized controlled trial. Setting: Humanitas Research Hospital, Milan, Italy. Participants: Ninety-two participants with age between 40 and 80 years and urinary incontinence after robot-assisted laparoscopic prostatectomy. Intervention: Participants were randomized into an action and cue observation ( n = 46) or control ( n = 46) group undergoing an 8-week home-based pelvic floor muscle training. Action and cue observation group observed video clips showing exercises synchronized with a visual cue indicating the correct pelvic floor muscle activation timing and imitated the observed tasks. Control group observed landscape video clips and performed the same exercises of experimental group. Main measures: A blinded physiotherapist assessed participants for urinary leakages (24-h pad test), symptom severity (International Prostate Symptoms Score and International Prostate Symptoms Score - Quality of Life), quality of life (International Consultation on Incontinence Questionnaire - Short Form), and erectile dysfunction (International Index of Erectile Function) before and after the training. Results: All participants improved urinary leakages, symptom severity, and quality of life after training. Action and cue observation group revealed significantly larger improvements in 24-h pad test (mean difference: 106.1 g, 95% CI: 13.4 g, 199.1 g, p = .037) than control group. Conclusions: Home-based pelvic floor muscle training with action and cue observation led to larger improvements in urinary continence compared to the same training without action and cue observation after prostatectomy.
- 24 June 2024
- Published by Wiley in BJU International
- Vol. 134 (4) , 561-563
Preliminary findings on vitamin D 25‐ OH levels in urine analysis: implications for clinical practice
- 24 June 2024
- Published by Wiley in BJU International
- Vol. 134 (4) , 561-563
Preliminary findings on vitamin D 25‐ OH levels in urine analysis: implications for clinical practice
- Open Access
Preoperative Age and Its Impact on Long-Term Renal Functional Decline after Robotic-Assisted Partial Nephrectomy: Insights from a Tertiary Referral Center
Background and Objectives: to investigate the impact of age on renal function deterioration after robotic-assisted partial nephrectomy (RAPN) focusing on a decline to moderate and severe forms of chronic kidney disease (CKD). Materials and Methods: This is a single center prospective analysis of patients who underwent RAPN. The outcomes include the development of de novo CKD-S 3a [estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2)] and de novo CKD-S 3b (eGFR < 45 mL/min/1.73/m2). Multivariable analysis (MVA) via Cox regression identified predictors for CKD-S 3a/b. Kaplan –Meier Analyses (KMA) were fitted for survival assessment. Multivariable linear regression was utilized to identify the predictors of last-eGFR. Results: Overall, 258 patients were analyzed [low age (70) n = 54 (20.9%)] with a median follow-up of 31 (IQR 20–42) months. MVA revealed an increasing RENAL score [Hazard Ratio (HR) 1.32, p = 0.009], age 50–70 (HR 6.21, p = 0.01), age ≥ 70 (HR 10.81, p = 0.001), increasing BMI (HR 1.11, p < 0.001) and preoperative CKD 2 (HR 2.43, p = 0.014) are independent risk factors associated with an increased risk of CKD-S 3a; conversely, post-surgical acute kidney injury was not (p = 0.83). MVA for CKD-S 3b revealed an increasing RENAL score (HR 1.51, p = 0.013) and age ≥ 70 (HR 2.73, p = 0.046) are associated with an increased risk of CKD-S 3b. Linear regression analysis revealed increasing age (Coeff. −0.76, p < 0.001), increasing tumor size (Coeff. −0.31, p = 0.03), and increasing BMI (Coeff. −0.64, p = 0.004) are associated with decreasing eGFR at last follow-up. We compare the survival distribution of our cohort stratified by age elderly patients experienced worsened CKD-S 3a/b disease-free survival (p < 0.001; p < 0.001, respectively). Conclusions: Age is independently associated with a greater risk of significant and ongoing decline in kidney function following RAPN. Recognizing the impact of aging on renal function post-surgery can guide better management practices. Further investigations are required.
Open AccessPreoperative Age and Its Impact on Long-Term Renal Functional Decline after Robotic-Assisted Partial Nephrectomy: Insights from a Tertiary Referral Center
Background and Objectives: to investigate the impact of age on renal function deterioration after robotic-assisted partial nephrectomy (RAPN) focusing on a decline to moderate and severe forms of chronic kidney disease (CKD). Materials and Methods: This is a single center prospective analysis of patients who underwent RAPN. The outcomes include the development of de novo CKD-S 3a [estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2)] and de novo CKD-S 3b (eGFR < 45 mL/min/1.73/m2). Multivariable analysis (MVA) via Cox regression identified predictors for CKD-S 3a/b. Kaplan –Meier Analyses (KMA) were fitted for survival assessment. Multivariable linear regression was utilized to identify the predictors of last-eGFR. Results: Overall, 258 patients were analyzed [low age (70) n = 54 (20.9%)] with a median follow-up of 31 (IQR 20–42) months. MVA revealed an increasing RENAL score [Hazard Ratio (HR) 1.32, p = 0.009], age 50–70 (HR 6.21, p = 0.01), age ≥ 70 (HR 10.81, p = 0.001), increasing BMI (HR 1.11, p < 0.001) and preoperative CKD 2 (HR 2.43, p = 0.014) are independent risk factors associated with an increased risk of CKD-S 3a; conversely, post-surgical acute kidney injury was not (p = 0.83). MVA for CKD-S 3b revealed an increasing RENAL score (HR 1.51, p = 0.013) and age ≥ 70 (HR 2.73, p = 0.046) are associated with an increased risk of CKD-S 3b. Linear regression analysis revealed increasing age (Coeff. −0.76, p < 0.001), increasing tumor size (Coeff. −0.31, p = 0.03), and increasing BMI (Coeff. −0.64, p = 0.004) are associated with decreasing eGFR at last follow-up. We compare the survival distribution of our cohort stratified by age elderly patients experienced worsened CKD-S 3a/b disease-free survival (p < 0.001; p < 0.001, respectively). Conclusions: Age is independently associated with a greater risk of significant and ongoing decline in kidney function following RAPN. Recognizing the impact of aging on renal function post-surgery can guide better management practices. Further investigations are required.